ULF

Poxel Reports Financial Results for First Half 2023 and Provides a Corporate Update

Retrieved on: 
Tuesday, September 26, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, Diabetes, ULF, Adrenoleukodystrophy, Prescription, Plasma, JPY, Patent, Patient, Serono, Merck, R, Estonia, POC, Pioglitazone, Sumitomo Group, Disease, Male, NASH, Pharmacokinetics, Sumitomo Pharma, EPO, Fatty liver disease, Leukodystrophy, Marshal of France, Rare, Kidney, Conference, Safety, Abstract, DPP4, ALD, JDS, Merck Serono, European Patent Office, Biomarker, DSM-IV codes, AMN, IRIS, Scientific communication, United States patent law, SGLT2, VLCFA, EUR, European Patent Convention, Pharmacology, TZD, Pharmaceutical industry, Medical device, Imeglimin, Euronext

POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its financial results for the period ended June 30, 2023 and provided a corporate update.

Key Points: 
  • POXEL SA (Euronext: POXEL - FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announced its financial results for the period ended June 30, 2023 and provided a corporate update.
  • For the Sumitomo Pharma FY 2023, as a conservative assumption in line with Sumitomo Pharma’s forecast, Poxel expects to receive 8% royalties on TWYMEEG net sales.
  • On July 5th, Poxel was chosen as the winner of the 2023 edition of the I-nov contest for its program in ALD.
  • This recently issued patent provides additional protection through 2041, with the potential for an additional 5 years through patent term extension.

Poxel Reports Cash and Revenue for the Second Quarter and First Half 2023 and Provides Corporate Update

Retrieved on: 
Wednesday, August 30, 2023
Health, Other Science, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Diabetes, ULF, Senior, Adrenoleukodystrophy, Prescription, Plasma, JPY, Patent, Patient, Serono, Merck, R, Estonia, POC, Pioglitazone, Sumitomo Group, Disease, Male, NASH, Pharmacokinetics, USD, EPO, Fatty liver disease, Leukodystrophy, Marshal of France, Rare, Kidney, Conference, Safety, Abstract, DPP4, ALD, JDS, Merck Serono, European Patent Office, Biomarker, DSM-IV codes, Communication, AMN, IRIS, Scientific communication, Sumitomo Pharma, United States patent law, SGLT2, VLCFA, European Patent Convention, Pharmacology, TZD, Pharmaceutical industry, Medical device, Cryptocurrency, Imeglimin, EUR, Euronext

These factors have resulted in a much higher increase in demand for TWYMEEG than expected by Sumitomo, and thus inventories are temporarily tight.

Key Points: 
  • These factors have resulted in a much higher increase in demand for TWYMEEG than expected by Sumitomo, and thus inventories are temporarily tight.
  • For the Sumitomo FY 2023, as a conservative assumption in line with Sumitomo’s forecast, Poxel expects to receive 8% royalties on TWYMEEG net sales.
  • On July 5th, Poxel was chosen as the winner of the 2023 edition of the I-nov contest for its program in ALD.
  • As of June 30, 2023, cash and cash equivalents were EUR 7.6 million (USD 8.2 million), as compared to EUR 13.1 million (USD 14.0 million) as of December 31, 2022.

Presidio Medical™ Announces $72M Equity Fundraising Led by Deerfield

Retrieved on: 
Monday, June 26, 2023
Science, Cardiology, Other Science, Health, Medical Devices, Health Technology, Clinical Trials, Other Health, Nobel Prize, Human, ULF, U.S. Venture Partners, Research, Pain, Animal, Patient, Science Translational Medicine, Ultra, ARD International Music Competition, Chronic pain, Pharmaceutical industry

Proceeds will be used to expand the team, scale manufacturing, and conduct long-term, pivotal clinical studies of Presidio’s unique ULF™ SCS system.

Key Points: 
  • Proceeds will be used to expand the team, scale manufacturing, and conduct long-term, pivotal clinical studies of Presidio’s unique ULF™ SCS system.
  • In conjunction with this financing David Neustaedter, Ph.D., Venture Partner, Deerfield Management Company, has joined Presidio’s Board of Directors.
  • Presidio Medical was founded in 2017 and is headquartered in South San Francisco, CA.
  • Presidio’s investors include Deerfield Management, Invus Opportunities, Action Potential Venture Capital, and ShangBay Capital.

Poxel Announces its Participation at Patient Association Conferences in Adrenoleukodystrophy

Retrieved on: 
Thursday, June 15, 2023
Biotechnology, Health, Genetics, Pharmaceutical, Clinical Trials, AMN, Male, ULF, NASH, Adrenoleukodystrophy, ALD, Scientific communication, DSM-IV codes, Patient, Fatty liver disease, Leukodystrophy, R, POC, Pharmacology, Conference, TZD, Pharmaceutical industry, Euronext

Poxel remains committed to discover, develop, and commercialize innovative therapies for patients suffering from serious chronic and rare diseases with underlying metabolic pathophysiology, starting with ALD.

Key Points: 
  • Poxel remains committed to discover, develop, and commercialize innovative therapies for patients suffering from serious chronic and rare diseases with underlying metabolic pathophysiology, starting with ALD.
  • PXL770 and PXL065 have demonstrated preclinically their efficacy in adrenomyeloneuropathy (AMN) and cerebral ALD (c-ALD) in mouse and human models1.
  • In line with his mission to bring therapeutic options to treat ALD, Poxel recently supported the Alex Leukodystrophy Charity during their Community Weekend, which took place from April 28th to May 1st in Birmingham, England.
  • This event brings together leukodystrophy sufferers and their families, alongside doctors, researchers and scientists from around the world to discuss leukodystrophies.

Presidio Medical™ Announces Executive Appointment

Retrieved on: 
Tuesday, March 21, 2023
Science, Cardiology, Other Science, Health, Medical Devices, Health Technology, Clinical Trials, Other Health, R&D, ULF, DME, Presidio, SJM, Program management, Cardiac resynchronization therapy, Organization, Development, Senior, Durable medical equipment, Acquisition, Divisional patent application, Supply chain, Patient, Ultra, Heart failure, Growth, Chronic pain, St. Jude Medical, Medical device, Management, Operation

Presidio Medical, Inc., a clinical-stage medical device company developing a transformational Ultra Low Frequency (ULF™) neuromodulation platform, announced that Scott Salys joined the Executive Team as Chief Research & Development and Operations Officer.

Key Points: 
  • Presidio Medical, Inc., a clinical-stage medical device company developing a transformational Ultra Low Frequency (ULF™) neuromodulation platform, announced that Scott Salys joined the Executive Team as Chief Research & Development and Operations Officer.
  • Mr. Salys joins Presidio from Abbott where he was most recently the Divisional Vice President of R&D of the Heart Failure business.
  • “We are thrilled to have someone with Scott’s breadth of experience across Operations, Supply Chain, and R&D join the Presidio team.
  • “I am excited to join this incredibly talented team and lead Presidio Medical through the next stage of clinical and product development.

Kohler and Phyn Offer Integration with Alarm.com for H2Wise Product Suite

Retrieved on: 
Wednesday, October 5, 2022
Quality of life, Ryder Cup, Whistling Straits, New, FORTUNE, IOT, Lighting, Alarm.com, District, Research, ULF, Builder, Professional Builder, Partnership, Technology, LOS, Kohler Co., Company, World, The National German Sustainability Award, Toll Brothers, Water, GPM, Core, Red Dot, Water supply, Weather, Solution, Engineering, Video game console, Insurance, Mail order, KOHLER

KOHLER, Wis. and LOS ANGELES, Oct. 5, 2022 /PRNewswire/ -- Kohler, a global leader in innovation and manufacturer of kitchen and bath products, and Phyn, the leader in intelligent water solutions, today announced that their suite of whole home monitoring products now integrates directly with Alarm.com, the leading platform for the intelligently connected property, creating a powerful all-inclusive water security system for homeowners. Kohler and Phyn have also partnered with Toll Brothers, the nation's leading builder of luxury homes, to offer the simple turnkey solution to its single-family residence customers.

Key Points: 
  • Kohler and Phyn have also partnered with Toll Brothers , the nation's leading builder of luxury homes, to offer the simple turnkey solution to its single-family residence customers.
  • By connecting Kohler H2Wise and Phyn products to the Alarm.com platform, users will be able to monitor and manage smart home devices through their Alarm.com app.
  • "We are very excited to offer Kohler's new H2Wise solution as an option for our Toll Brothers home buyers across the country.
  • Kohler H2Wise+ Powered by Phyn - H2Wise+ is professionally installed onto the main water line, thus providing the ability to shut off the main water supply automatically and remotely when a leak is detected.

Gramercy launches claims against Ukrainian oligarch Oleg Bakhmatyuk and US associate Nicholas Piazza over asset transfers

Retrieved on: 
Wednesday, December 8, 2021
Company, RICO, Complaint, AVG, Fraud, ULF, Racketeer Influenced and Corrupt Organizations Act, Oleg Bakhmatyuk, Freezing, Security (finance)

In addition to claims under RICO, the U.S. complaint includes claims for fraud, tortious interference, aiding and abetting and civil conspiracy, and seeks, inter alia, treble damages under RICO.

Key Points: 
  • In addition to claims under RICO, the U.S. complaint includes claims for fraud, tortious interference, aiding and abetting and civil conspiracy, and seeks, inter alia, treble damages under RICO.
  • Gramercy has also commenced a separate proceeding in Cyprus regarding transfers of material assets from ULF Group to a Cypriot entity owned and controlled by Bakhmatyuk.
  • Mr. Bakhmatyuk and others have already appeared in court through counsel to defend the Cyprus action.
  • ULF Group is among Ukraine's largest agricultural companies and owns the largest egg-producing business in Europe.

Gramercy launches claims against Ukrainian oligarch Oleg Bakhmatyuk and US associate Nicholas Piazza over asset transfers

Retrieved on: 
Wednesday, December 8, 2021
Company, RICO, Complaint, AVG, Fraud, ULF, Racketeer Influenced and Corrupt Organizations Act, Oleg Bakhmatyuk, Freezing, Security (finance)

In addition to claims under RICO, the U.S. complaint includes claims for fraud, tortious interference, aiding and abetting and civil conspiracy, and seeks, inter alia, treble damages under RICO.

Key Points: 
  • In addition to claims under RICO, the U.S. complaint includes claims for fraud, tortious interference, aiding and abetting and civil conspiracy, and seeks, inter alia, treble damages under RICO.
  • Gramercy has also commenced a separate proceeding in Cyprus regarding transfers of material assets from ULF Group to a Cypriot entity owned and controlled by Bakhmatyuk.
  • Mr. Bakhmatyuk and others have already appeared in court through counsel to defend the Cyprus action.
  • ULF Group is among Ukraine's largest agricultural companies and owns the largest egg-producing business in Europe.

Presidio Medical™ Announces Publication of ULF™ Neuromodulation Research in Science Translational Medicine

Retrieved on: 
Wednesday, August 25, 2021
Research, Surgery, Medical Devices, Clinical Trials, Biotechnology, Health, General Health, Other Science, Science, International Neuromodulation Society, University, Pain, Trial of the century, Physician, Sherrington, Research, AUS, Science Translational Medicine, Doctor of Philosophy, SCS, ULF, Clinical trial, Chronic pain, Patient, Physiology, Technology, Nervous system, Pharmaceutical industry, Dentistry

Presidio Medical, Inc. , a clinical-stage medical technology company developing a transformational neuromodulation platform, today announced research involving the companys novel ULF neuromodulation therapy has been published in Science Translational Medicine.

Key Points: 
  • Presidio Medical, Inc. , a clinical-stage medical technology company developing a transformational neuromodulation platform, today announced research involving the companys novel ULF neuromodulation therapy has been published in Science Translational Medicine.
  • The publication, titled Neuromodulation using ultra low frequency current waveform reversibly blocks axonal conduction and chronic pain, was a collaboration spanning three continents, and describes groundbreaking research on how ULF neuromodulation inhibits pain signals in pre-clinical animal models, computational models, and in a clinical trial.
  • The global effort included scientists and physicians at Kings College London (UK), University of Michigan (USA), Hunter Pain Specialists (AUS), and Presidio Medical, Inc. (USA).
  • The clinical stage, privately held medical device company, is developing a transformational neuromodulation technology platform with a first indication in the treatment of chronic pain.